chlorambucil,obinutuzumab,acalabrutinib
astrazeneca,roche,biogen,acerta pharma,nippon shinyaku,gsk
[]
 you are correct . the data for os advantage was presented on the 5-year follow up update at asco 2022, with a hr of 0.55 (p=0.0474) in favor of acala+o vs chl+o. here s the link: 
Oncologist.Rock Musician. Grill Master. Awesome Dad. Proud Brazilian. Director, Lymphoma and CLL Program and IEC Program @novanthealth